January 1, 2015 • Volume 75 • Number 1

BREAKING ADVANCES

1 Highlights from Recent Cancer Literature

FROM THE EDITOR’S CHAIR

3 A Perspective on Cancer as an Abortive Autoimmune Response to Altered-Self
George C. Prendergast

REVIEWS

5 Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk and George J. Weiner

11 Regulation of Epithelial–Mesenchymal Transition through SUMOylation of Transcription Factors
Maria V. Bogachek, James P. De Andrade, and Ronald J. Weigel

PRIORITY REPORT

16 The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients
Nicole M. Warrington, Tao Sun, Jingqin Luo, Robert C. McKintosh, Patricia C. Parkin, Sara Ganzhorn, Debra Spoljaric, Anne C. Albers, Amanda Merkelson, Douglas R. Stewart, David A. Stevenson, David Viskochil, Todd E. Druley, Jason T. Forys, Karlyne M. Reilly, Michael J. Fisher, Uti Tabori, Jeffrey C. Allen, Joshua D. Schiffman, David H. Gutmann, and Joshua B. Rubin

PRÉCIS: These results establishing a sex-specific role for cAMP regulation in affecting the risk of gliomas in NF1 patients may offer new rational strategies to reduce risk or treat brain tumors in this population.

CLINICAL STUDIES

22 Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

PRÉCIS: Although clinical application of oncolytic viruses as experimental therapies has frequently been challenged on the grounds of efficacy, more recently engineered vectors based on measles virus may offer effective options to treat certain advanced cancers such as metastatic ovarian cancer.

INTEGRATED SYSTEMS AND TECHNOLOGIES

31 A Noninvasive Procedure for Early-Stage Discrimination of Malignant and Precancerous Vocal Fold Lesions Based on Laryngeal Dynamics Analysis
Jakob Unger, Jörg Lohscheller, Maximilian Reiter, Katharina Eder, Christian S. Betz, and Maria Schuster

PRÉCIS: This study offers a proof of concept for a procedure to diagnose most types of laryngeal cancers, possibly helping avoid current invasive diagnostic procedures that are associated with greater time, morbidity, and cost.

MICROENVIRONMENT AND IMMUNOLOGY

40 Akt1 and Akt3 Exert Opposing Roles in the Regulation of Vascular Tumor Growth

PRÉCIS: These findings offer a preclinical proof of concept for the therapeutic utility of treating poorly understood vascular tumors such as angiosarcoma with S6K inhibitors.
# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 51   | Paradoxical Decrease in the Capture and Lymph Node Delivery of Cancer Vaccine Antigen Induced by a TLR4 Agonist as Visualized by Dual-Mode Imaging Deepak K. Kadayakkara, Michael J. Korrer, Jeff W.M. Bulse, and Hyam I. Levitsky  
Précis: An adjuvant molecule that enhances the therapeutic effects of a cancer vaccine was found paradoxically to reduce the efficiency of antigen delivery to lymph nodes, challenging what has been thought to be necessary in an effective adjuvant—at least as formed by expectations from studies of infectious disease vaccines. |
| 62   | Tropomodulin 1 Expression Driven by NF-κB Enhances Breast Cancer Growth Taku Ito-Kureha, Naohiko Koshikawa, Mizuki Yamamoto, Rentaro Sembha, Noritaka Yamaguchi, Tadashi Yamamoto, Motoharu Seiki, and Jun-ichiro Inoue  
Précis: These findings highlight a novel mechanistic linkage to help explain the NF-κB-dependent malignant phenotype of triple-negative breast cancer, with implications for defining useful theranostic targets in this aggressive disease. |
| 73   | Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts Keun-Woo Lee, So-Young Yeo, Chang Ohk Sung, and Seok-Hyung Kim  
Précis: Already known as a central contributor to EMT, which drives metastatic progression in cancer cells, the transcription factor Twist1 is also found to function in cancer-associated fibroblasts, where it appears to offer a compelling target to depromog the tumor-supporting features of the cancer microenvironment. |
| 86   | Intracellular Osteopontin Inhibits Toll-like Receptor Signaling and Impedes Liver Carcinogenesis Xiaoyu Fan, Chunyan He, Wei Jing, Xuyu Zhou, Rui Chen, Lei Gao, Minhui Zhu, Rongjie Lai, Hao Wang, Yajun Guo, and Jian Zhao  
Précis: Osteopontin is known to act in the tumor microenvironment to promote inflammatory processes that facilitate progression, but this study reveals that it also acts within macrophages that infiltrate budding liver tumors to achieve this end by altering Toll-like receptor signaling. |
| 98   | PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar Rhabdomyosarcoma Verena Thalhammer, Laura A. Lopez-Garcia, David Herrero-Martin, Regina Hecker, Dominik Laubscher, Maria E. Gierisch, Marco Wachtel, Peter Bode, Paolo Nanni, Bernd Blank, Ewa Kosielniaik, and Beat W. Schäfer  
Précis: These findings offer a preclinical proof of concept to target the mitotic kinase PLK1 as a rational strategy to treat an aggressive pediatric tumor. |
| 111  | LASP1 Is a HIF1α Target Gene Critical for Metastasis of Pancreatic Cancer Tiansuo Zhao, He Ren, Jing Li, Jing Chen, Huan Zhang, Wen Xin, Yan Sun, Lei Sun, Yongwei Yang, Junwei Sun, Xiuchao Wang, Song Gao, Chonghiao Huang, Huafeng Zhang, Shengyu Yang, and Jiuhui Hao  
Précis: This study identifies a key mediator of metastasis in pancreatic ductal carcinomas that are typically already disseminated at the time of diagnosis, a central challenge in the management of this disease. |
| 120  | VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells Matteo Curtarello, Elisabetta Zulato, Giorgia Nardo, Silvia Valtorta, Giulia Guzzo, Elisabetta Rossi, Giovanni Esposito, Aichi Msaki, Anna Pastó, Andrea Rasola, Luca Persano, Francesco Ciccarese, Roberta Bertorelle, Sergio Todde, Mario Plebani, Henrike Schroer, Stefan Walenta, Wolfgang Mueller-Klieser, Alberto Amadori, Rosa Maria Moresco, and Stefano Indraccolo  
Précis: These findings suggest that the application of antiangiogenic therapy in cancer selects for metabolic traits of tumors that not only confer treatment resistance but also potentially have a more aggressive character, challenging a central tenet of antiangiogenic therapy as inherently less susceptible to the evolution of resistance. |
Précis: These findings provide a strong rationale to clinically evaluate foretinib immediately as a therapy for a defined subset of patients with the most common form of malignant pediatric brain tumor. |
159 Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
Shi Hu, Wenyuan Fu, Weihao Xu, Yang Yang, Hiroaki Takeda, and Wangdong Zhu

Précis: These results establish a new principle to achieve combined HER receptor inhibition and limit drug resistance using a single antibody.

171 Genetic Disruption of Lactate/H+ Symporters (MCTs) and Their Subunit CD147/BASIGIN Sensitizes Glycolytic Tumor Cells to Phenformin
Ibtissam Marchiq, Renaud Le Floch, Danièle Roux, Marie-Pierre Simon, and Jacques Pousyssegur

Précis: This study offers preclinical proof of concept for targeting lactic acid export as a therapeutic approach, the effect of which can be magnified by coupling it with phenformin, an anti-diabetic biguanide drug.

181 Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
Anna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, David C. Essaka, Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey A. Ecsedy, Jeffrey N. Johnston, and Ann Richmond

Précis: These findings offer preclinical proof of concept for a combination drug treatment that leverages both senescence and immune surveillance to improve therapeutic outcomes.
ABOUT THE COVER

Timing of GLA in relation to vaccination impacts the pattern of OT1 cell accumulation. Representative bioluminescent images show site-specific accumulation of OT1 cells in different groups of mice 4 days post hind footpad vaccination. Vaccine-primed T cells accumulated in the draining lymph nodes in mice that received GVAX only or when GLA 24 was given 24 hrs post GVAX. However, when GLA is coadministered with GVAX, a systemic pattern of T-cell accumulation was observed. For details, see article by Kadayakkaza and colleagues on page 51.
75 (1)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/75/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.